Laboratory medicine and medical oncology: the tale of two Cinderellas

Melichar, Bohuslav

doi:10.1515/cclm-2012-0496

Cited by 46 publications

(31 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The involvement of physicians of different specialties has resulted in cure rates that were not imaginable only few decades ago. Among other specialties, laboratory medicine plays an increasingly important role in defining the therapeutic strategy and daily management of cancer patients (1). The importance of laboratory medicine is increasing with the advent of targeted therapy that has transformed the treatment of many tumors.…”

Section: Introductionmentioning

confidence: 99%

Neopterin as a biomarker of immune response in cancer patients

Melichar¹,

Spisarová²,

Bartoušková³

et al. 2017

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Neopterin as a biomarker of immune response in cancer patients

Melichar¹,

Spisarová²,

Bartoušková³

et al. 2017

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

“…Laboratory medicine is currently playing an increasingly important role in the management of cancer patients [22]. The present report illustrates the utilization of biomarkers in monitoring the activation of the immune system and toxicity of the therapy.…”

Section: Discussionmentioning

confidence: 90%

Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract:We report a patient who presented with synchronous second primary human epidermal growth factor receptor (HER)-2-positive breast cancer and rectal cancer that both required simultaneous neoadjuvant therapy. A modified regimen combining anti-HER-2 monoclonal antibody trastuzumab with chemotherapy and external beam radiation was selected. An organ-preserving surgical procedure was possible both in the breast and the rectum. Citrulline decreased rapidly after the start of the treatment, and then gradually returned to pre-treatment levels after the completion of chemoradiation. Urinary neopterin concentrations exhibited a fluctuating course. Both serum neopterin and C-reactive protein concentrations were more or less stable during the initial administration of trastuzumab, paclitaxel and carboplatin and then increased steeply during chemoradiation and subsequently declined to pre-treatment levels during the weekly trastuzumab administration. Changes were observed in the serum retinol concentrations. A decline in lymphocyte counts was accompanied by marked changes in peripheral blood cell count-derived ratios. The present case report demonstrates a successful combination of two neoadjuvant regimens in a patient with two synchronous different second primary tumors. Data from this case also illustrate the use of biomarkers for monitoring of intensive therapeutic regimens in medical and radiation oncology.

show abstract

“…Predictive biomarkers play an increasingly important role in medical oncology 39 , but, unfortunately, there is currently no information on clinical, pathological or laboratory predictive factors and/or biomarkers that might help in identifying HCC patients likely to benefit from HAI. One important set of biomarkers is associated with the immune response.…”

Section: Discussionmentioning

confidence: 99%

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Melichar¹,

Dvořák²,

Ferko³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

Self Cite

View full text Add to dashboard Cite

Aim. The aim of the present study was to evaluate a single center experience with hepatic arterial infusion (HAI) in patients with hepatocellular carcinoma. Methods. A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007. Results. Most patients were treated with an HAI of doxorubicin and cisplatin combined with 5-fluorouracil and folinic acid. The response was not evaluable in the majority of patients, predominantly because of associated surgical procedure or because only one cycle of HAI was administered. The median progression-free survival was 7.7 months. The median survival of all patients was 12.2 months (5-year survival 5%). Serious adverse events were observed in 5 patients, and one patient died of liver failure in association with the administration of HAI. Conclusion. The data show the limited efficacy of HAI in patients with hepatocellular carcinoma.

show abstract

Laboratory medicine and medical oncology: the tale of two Cinderellas

Cited by 46 publications

References 118 publications

Neopterin as a biomarker of immune response in cancer patients

Neopterin as a biomarker of immune response in cancer patients

Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Contact Info

Product

Resources

About